e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Sarcoidosis: pathogenesis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effect of exercise on serum amyloid a levels in patients with sarcoidosis: A preliminary report
George Vavougios (Larissa, Greece), George Vavougios, Periklis Panagis, Eleni Karetsi, Ioannis Papanikolaou, Fotini Bardaka, Panagiotis Maragozidis, Vasileios Stavrous, Konstantinos Gourgoulianis, Zoe Daniil
Source:
International Congress 2015 – Sarcoidosis: pathogenesis
Session:
Sarcoidosis: pathogenesis
Session type:
Poster Discussion
Number:
3324
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
George Vavougios (Larissa, Greece), George Vavougios, Periklis Panagis, Eleni Karetsi, Ioannis Papanikolaou, Fotini Bardaka, Panagiotis Maragozidis, Vasileios Stavrous, Konstantinos Gourgoulianis, Zoe Daniil. The effect of exercise on serum amyloid a levels in patients with sarcoidosis: A preliminary report. Eur Respir J 2015; 46: Suppl. 59, 3324
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Pulmonary sarcoidosis
Definition and history of sarcoidosis
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Is there a correlation between inflammatory status and exercise capacity in patients with bronchiectasis? Preliminary results
Source: International Congress 2015 – Physiotherapy assessment and techniques in pulmonary and non-pulmonary conditions
Year: 2015
The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?
Source: International Congress 2017 – Rare diseases
Year: 2017
Analysis of serum prohepcidin and hepcidin levels in COPD patients by stages and by patient cathegory
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Serum leptin, adponectin and its tissue expression in COPD patients with osteopenic syndrome
Source: International Congress 2015 – COPD: notable points
Year: 2015
Effect of isolated pulmonary rehabilitation vs. associated with a specific protein supplement on exercise test in patients with bronchiectasis: A randomized study
Source: International Congress 2015 – Latest insights into pulmonary rehabilitation
Year: 2015
The value of cardiopulmonary exercise testing in sarcoidosis
Source: International Congress 2015 – Clinical exercise physiology in health and disease
Year: 2015
C-reactive protein and pulmonary tuberculosis: What correlation with disease severity
Source: International Congress 2015 – Management of TB: a patient focus
Year: 2015
Predictors of functional exercise capacity in patients with early stage sarcoidosis
Source: Annual Congress 2013 –Assessment methods involved in the physiotherapy treatment in different patient populations
Year: 2013
Investigation of KL-6 levels in patients with IPF- OSA overlap syndrome: Preliminary results
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Leptin, inflammatory biomarkers and body composition in patients with sarcoidosis
Source: International Congress 2015 – Sarcoidosis: pathogenesis
Year: 2015
Serum C-reactive protein concentrations in patients with sarcoidosis: can be taken this simple test as an activation marker in sarcoidosis?
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004
Levels of YKL-40 in serum and sputum of patients diagnosed with hypersensitivity pneumonitis: A pilot study.
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: mechanistic insights and prognostic markers
Year: 2018
Sarcoidosis: serum and imaging biomarkers
Source: Eur Respir Monogr 2022; 96: 107-121
Year: 2022
TNF-alpha, IL-8, IL-6 levels in serum of sarcoidosis patients with different clinical course
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013
A pilot study of the serum cytokine (IL-6 and TNF-α) and C-reactive protein response to fixed acute exercise before and after a 7-week rehabilitation programme in COPD patients
Source: Annual Congress 2006 - Physiological responses to rehabilitation
Year: 2006
C-reactive protein: Its correlations with pulmonary function, physical capacity and anthropometric measurements in patients with metabolic syndrome
Source: International Congress 2014 – Physiotherapy assessment and techniques in respiratory and non-respiratory conditions
Year: 2014
The diagnostic value of serum soluble CD 14 and IL-10 levels in newly diagnosed pulmonary tuberculosis patients and the relationship with disease extensity
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013
Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study
Source: Eur Respir J 2010; 35: 540-548
Year: 2010
Serum IL-17 and IL-18 levels in asthma-COPD overlap syndrome patients
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
Late Breaking Abstract - A composite serum biomarker index for the diagnosis of systemic sclerosis associated interstitial lung disease: a multicentre, observational, cohort study
Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept